Efficacy and Safety of Topical Nonivamide/Nicoboxil Fixed Dose Combination (Noni) in Acute Low Back Pain (A-Lbp) : a Randomised, Placebo Controlled Trial
Morressier, 2017
Online
unknown
CUMULATIVE PROPORTION OF RESPONDERS ANALYSIS (CPRA) OF A RANDOMIZED, CONTROLLED TRIAL INVESTIGATING THE EFFECTS OF THE FIXED DOSE COMBINATION (FDC) NICOBOXIL/NONIVAMIDE (FINALGONu00ae), NICOBOXIL, NONIVAMIDE AND PLACEBO OINTMENT FOR THE TREATMENT OF ACUTE LOW BACK PAINT. Weiser, R. Lange, C. HolmSanofi Aventis Deutschland GmbHBackgroundA multicenter, active and placebo-controlled, double-blind, randomized trial in 805 patients has demonstrated pronounced analgesic efficacy of nicoboxil/nonivamide ointment (Finalgonu00ae) for treating acute low back pain. Pain intensity was assessed by the use of a numerical rating (range 0u201310) scale. Efficacy of the FDC versus placebo, expressed as pain intensity difference (PID) versus baseline, was shown as early as 4h after onset of treatment and for the entire treatment period (up to 4 days; Eur J Pain 20 (2016) 263). Here we present a detailed CPRA. MethodsAt 8h after treatment, and at the last individual treatment day (LID) the percentages of patients with u2018minimum-/moderate-/substantial-/clinical benefit; almost complete pain reliefu2019 (i.e. 15/30/50/90% PID), and corresponding numbers needed to treat (NNT) for the FDC compared to placebo (PLA) were calculated.ResultsAt 8h, the FDC[PLA] provided 15% PID for 77.5% [43.5%], 30% PID for 56.9% [25.1%], 50% PID for 29.9% [9.9%], and 90% PID for 4.9% [1.1%] of patients, resulting in NNT of 2.9, 3.1, 5.0, and 26.1 compared to PLA (p
Titel: |
Efficacy and Safety of Topical Nonivamide/Nicoboxil Fixed Dose Combination (Noni) in Acute Low Back Pain (A-Lbp) : a Randomised, Placebo Controlled Trial
|
---|---|
Autor/in / Beteiligte Person: | Holm, C. |
Link: | |
Veröffentlichung: | Morressier, 2017 |
Medientyp: | unknown |
Sonstiges: |
|